• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

FDA Approves New Type 2 Diabetes Drugs


Medications expected to improve blood sugar control in children 10 years and older.

Close up of Measuring Blood Sugar Level to Child. Image Credit: Adobe Stock Images/VadimGuzhva

Image Credit: Adobe Stock Images/VadimGuzhva

Earlier this week, the FDA announced the approval of Jardiance and Synjardy, created as additions to diet and exercise for pediatric type 2 diabetes. Reportedly, these approvals offer a new class of oral medicines for the treatment of type two diabetes in children.

Empagliflozin, the active ingredient in Jardiance and Synjardy, works by increasing the excretion of glucose in the urine.

"Compared to adults, children with type 2 diabetes have limited treatment options, even though the disease and symptom onset generally progress more rapidly in children," said Michelle Carey, MD, MPH, associate director for therapeutic review for the division of diabetes, lipid disorders, and obesity in the FDA's Center for Drug Evaluation and Research. "Today's approvals provide much-needed additional treatment options for children with type 2 diabetes."

Reference: FDA Approves New Class of Medicines to Treat Pediatric Type 2 Diabetes. PR Newswire. June 20, 2023. Accessed June 23, 2023. https://www.prnewswire.com/news-releases/fda-approves-new-class-of-medicines-to-treat-pediatric-type-2-diabetes-301855985.html

Related Videos
Related Content